Elicio Therapeutics Files 8-K

Ticker: ELTX · Form: 8-K · Filed: Dec 12, 2024 · CIK: 1601485

Elicio Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyElicio Therapeutics, Inc. (ELTX)
Form Type8-K
Filed DateDec 12, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing

TL;DR

Elicio Therapeutics filed a standard 8-K, check for material updates.

AI Summary

Elicio Therapeutics, Inc. filed an 8-K on December 12, 2024, reporting under Regulation FD Disclosure and Other Events. The company, formerly known as Angion Biomedica Corp., is incorporated in Delaware and headquartered in Boston, MA. This filing does not contain specific financial transactions or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates that Elicio Therapeutics is making a regulatory disclosure. Investors should review the details within the filing for any potential material information.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not disclose any specific negative or positive material events.

Key Players & Entities

  • Elicio Therapeutics, Inc. (company) — Registrant
  • Angion Biomedica Corp. (company) — Former Company Name
  • December 12, 2024 (date) — Date of Report
  • Boston, Massachusetts (location) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing by Elicio Therapeutics?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report on Other Events, as indicated in the filing.

When was this 8-K report filed?

This 8-K report was filed on December 12, 2024.

What was Elicio Therapeutics' former company name?

Elicio Therapeutics, Inc. was formerly known as Angion Biomedica Corp.

Where are Elicio Therapeutics' principal executive offices located?

Elicio Therapeutics' principal executive offices are located at 451 D Street, 5th Floor, Boston, Massachusetts.

Under which section of the Securities Exchange Act is this 8-K filed?

This 8-K is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.

Filing Stats: 582 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-12-12 07:05:48

Key Financial Figures

  • $0.01 — nge on which registered) Common Stock, $0.01 par value per share ELTX The Nasdaq Cap

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 12, 2024, Elicio Therapeutics, Inc. (the "Company") uploaded a copy of its corporate presentation to the Company's website, which presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

01 Other Events

Item 8.01 Other Events. On December 12, 2024, the Company issued a press release announcing updated results from its ELI-002 Phase 1 AMPLIFY-201 study at the ESMO Immuno-Oncology Congress 2024 taking place from December 11-13, 2024, in Geneva, Switzerland. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Corporate Presentation dated December 12, 2024. 99.2 Press Release dated December 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elicio Therapeutics, Inc. By: /s/ ROBERT CONNELLY Date: December 12, 2024 Robert Connelly President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.